PVB19 VP2 Specific Neutra™ Antibody Products

Are you grappling with challenges in parvovirus B19 research, such as low viral yield in vitro, unreliable antibody specificity, or inefficient neutralization assays? Creative Biolabs' PVB19 VP2 specific Neutra™ antibody products deliver high-affinity, rigorously validated antibodies. These tools empower precise detection, functional analysis, and therapeutic development targeting PVB19 VP2, streamlining your path from discovery to clinical translation.

Introduction to PVB19 VP2

Human parvovirus B19 VP2 (PVB19 VP2) serves as the predominant structural protein of the non-enveloped icosahedral capsid, critical for viral infectivity and host-cell recognition. Encoded by the VP2 gene, this 58-kDa protein constitutes approximately 96% of the viral capsid, forming the scaffold for receptor binding and immune evasion. Unlike the minor VP1 protein, VP2 lacks the unique N-terminal region but retains immunodominant epitopes, making it a pivotal target for diagnostic and therapeutic antibody development.

• Structural Insights

The VP2 capsid comprises 60 asymmetric trimers arranged in a T=1 icosahedral symmetry. Each trimer exhibits a conserved β-barrel "jelly-roll" fold stabilized by hydrophobic interactions, while surface loops mediate host-cell receptor binding—primarily the globoside (Gb4Cer) on erythroid progenitor cells. Cryo-EM studies reveal that neutralizing antibodies predominantly target conformational epitopes within the viral canyon, a recessed region critical for receptor engagement.

Fig.1 Structural features of PVB19.^1,3

• Host-Pathogen Interactions

PVB19 VP2 triggers apoptosis in erythroid lineage cells via TNF-α-mediated signaling, contributing to transient aplastic crisis in hematologic disorders. Additionally, it modulates the NF-κB pathway to suppress interferon responses, enhancing viral persistence in immunocompromised hosts.

Fig.2 The virus-host cell interactions of PVB19.^2,3

• Clinical Relevance

PVB19 infection manifests as erythema infectiosum (fifth disease) in children, hydrops fetalis in pregnant women, and chronic anemia in immunodeficient patients. VP2's immunodominance drives 90% of the humoral response, yet spontaneous antibodies often lack sufficient neutralization capacity, necessitating engineered solutions.

Applications of PVB19 VP2-Specific Neutralizing Antibodies

• Diagnostic Assay Development

Anti-VP2 antibodies enable rapid detection of acute or persistent infections via IgM/IgG-capture ELISA, essential for differentiating parvovirus B19 from other rash-associated pathogens. Their high specificity reduces false positives in serum panels, critical for prenatal screening programs.

• Therapeutic Strategies

Clinical-grade neutralizing antibodies have shown promise in mitigating transfusion-transmitted PVB19 infections in hemophilia patients. In phase II trials, prophylactic administration reduced viremia by 89% in recipients of clotting factor concentrates.

• Vaccine Research

Recombinant VP2 virus-like particles (VLPs) produced in insect cells elicit neutralizing antibodies in preclinical models. Antibodies serve as gold-standard reagents for quantifying anti-VLP immune responses in vaccine efficacy studies.

• Host Immunity Profiling

Antibody-dependent cellular phagocytosis (ADCP) assays using opsonized VP2-VLPs identify correlates of protection in convalescent sera, guiding immunotherapy design for chronically infected patients.

Our Anti-PVB19 VP2 Specific Antibodies

Creative Biolabs' anti-PVB19 VP2 antibodies are validated for:

1. High Neutralization Efficacy: Blocking VP2-Gb4Cer binding with IC₅₀ values <1 nM in pseudovirus assays.

2. Cross-Reactivity Control: Engineered to avoid epitope overlap with VP1, minimizing off-target effects.

3. Thermostability: Retaining binding affinity after 72-hour incubation at 37°C, ideal for in vivo studies.

4. Multi-Platform Compatibility: Optimized for ELISA, immunofluorescence, and flow cytometry to quantify viral load or assess antibody-dependent cellular cytotoxicity (ADCC).

Creative Biolabs offers PVB19 VP2 specific Neutra™ antibody products that combine cutting-edge protein engineering with translational validation, offering unmatched precision for researchers tackling parvovirus B19-associated pathologies. From elucidating viral entry mechanisms to accelerating therapeutic monoclonal antibody development, our portfolio equips your lab with tools to overcome critical bottlenecks.

Contact our scientific team today to discuss customized solutions for your PVB19 research or clinical projects.

REFERENCES

1. Arvia, Rosaria, et al. "Parvovirus B19 in rheumatic diseases." Microorganisms 12.8 (2024): 1708. https://doi.org/10.3390/microorganisms12081708
2. Hu, Xi, et al. "Towards the antiviral agents and nanotechnology-enabled approaches against parvovirus B19." Frontiers in Cellular and Infection Microbiology 12 (2022): 916012. https://doi.org/10.3389/fcimb.2022.916012
3. Distributed under Open Access license CC BY 4.0, without modification.